[1]邱煜焱,杨旭,苟文军,等.2型糖尿病患者血清lncRNA MALAT1表达水平与视网膜病变的关系[J].眼科新进展,2022,42(12):971-974.[doi:10.13389/j.cnki.rao.2022.0199]
　QIU Yuyan,YANG Xu,GOU Wenjun,et al.Relationship between the expression level of long non-coding ribonucleic acid metastasis associated lung adenocarcinoma transcript 1 in serum and retinopathy in patients with type 2 diabetes mellitus[J].Recent Advances in Ophthalmology,2022,42(12):971-974.[doi:10.13389/j.cnki.rao.2022.0199]
点击复制

2型糖尿病患者血清lncRNA MALAT1表达水平与视网膜病变的关系/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年12期
页码:
971-974
栏目:
应用研究
出版日期:
2022-12-05

文章信息/Info

Title:
Relationship between the expression level of long non-coding ribonucleic acid metastasis associated lung adenocarcinoma transcript 1 in serum and retinopathy in patients with type 2 diabetes mellitus
作者:
邱煜焱; 杨旭; 苟文军; 刘思源; 康海军; 刘灵琳
629000　四川省遂宁市，遂宁市中心医院眼科
Author(s):
QIU Yuyan; YANG Xu; GOU Wenjun; LIU Siyuan; KANG Haijun; LIU Linglin
Department of Ophthalmology,Suining Central Hospital,Suining 629000，Sichuan Province,China
关键词:
糖尿病; 长链非编码RNA; 人肺腺癌转移相关转录本1; 糖尿病视网膜病变; 预测价值
Keywords:
diabetes mellitus;  long non-coding ribonucleic acid;  metastasis associated lung adenocarcinoma transcript 1;  diabetic retinopathy;  value for predicting
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2022.0199
文献标志码:
A
摘要:
目的　探讨2型糖尿病（T2DM）患者血清长链非编码RNA-人肺腺癌转移相关转录本1（MALAT1）表达水平与糖尿病视网膜病变（DR）的关系。方法　回顾性分析2019年1月至2021年6月本院184例（368眼）T2DM患者的临床资料，分为3组：非DR组（T2DM无并发症患者54例）、非增生组（T2DM合并非增生型DR患者62例）、增生组（T2DM合并增生型DR患者68例）。全自动生化检测仪检测患者谷丙转氨酶（AST）、谷草转氨酶（ALT）、血肌酐（Scr）、血尿酸（SUA）、总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、空腹血糖（FBG）。酶联免疫吸附实验检测患者白细胞介素6（IL-6）和肿瘤坏死因子α（TNF-α）。用化学发光免疫分析法检测患者空腹胰岛素（Fins），计算胰岛素抵抗指数（HOMA-IR）。用离子交换高效液相色谱法检测患者糖化血红蛋白（HbA1c）。实时荧光定量PCR检测患者血清MALAT1表达水平。用Pearson分析MALAT1与患者其余临床指标的相关性；采用二元Logistic回归分析T2DM患者发生DR的影响因素；采用受试者工作特征曲线（ROC）分析MALAT1预测DR的价值，计算曲线下面积（AUC）、灵敏度和特异度。结果　增生组和非增生组患者年龄、病程、LDL-C、HbA1c、HOMA-IR、IL-6、TNF-α和MALAT1均高于非DR组（均为P<0.05），且增生组患者以上各指标均高于非增生组（均为P<0.05）。三组患者性别、体重指数、高血压占比、高脂血症占比、吸烟占比、饮酒占比、AST、ALT、Scr、SUA、TC、TG、HDL-C、FBG组间比较差异均无统计学意义（均为P>0.05）。MALAT1与病程、LDL-C、HbA1c、HOMA-IR、IL-6、TNF-α均呈正相关（均为P<0.05），与AST、ALT、Scr、SUA、TC、TG、HDL-C、FBG均无相关性（均为P>0.05）。年龄、病程、LDL-C、HbA1c、HOMA-IR、IL-6、TNF-α和MALAT1是T2DM患者发生DR的独立影响因素（均为P<0.05）。MALAT1预测T2DM患者发生DR的AUC为0.843，高于LDL-C（0.464）、HbA1c（0.606）、HOMA-IR（0.601）、IL-6（0.663）、TNF-α（0.694）。MALAT1预测T2DM患者发生DR的灵敏度和特异度分别为89.34%和71.55%。结论　T2DM患者发生DR时血清MALAT1表达水平升高，并且与糖脂代谢、炎症指标及病情进展相关。MALAT1可能是预测T2DM发生DR的生物学指标。
Abstract:
Objective　To explore the relationship between the expression level of long non-coding ribonucleic acid metastasis associated lung adenocarcinoma transcript 1 (lncRNA MALAT1) in serum and the diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). Methods　The clinical data of 184 patients (368 eyes) with T2DM admitted to our hospital from January 2019 to June 2021 were analyzed retrospectively. They were divided into three groups: non-DR group (54 T2DM patients without complications), non-proliferation group (62 patients with T2DM combined with non-proliferative DR), and proliferation group (68 patients with T2DM and proliferative DR). The levels of glutamic-pyruvic transaminase (AST), glutamic-oxaloacetic transaminase (ALT), serum creatinine (Scr), serum uric acid (SUA), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and fasting blood glucose (FBG) were detected by the automatic biochemical detector. The interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) were detected by enzyme-linked immunosorbent assay. Fasting insulin (Fins) was detected by chemiluminescence immunoassay, and homeostasis model assessment of insulin resistance (HOMA-IR) was carried out. Glycosylated hemoglobin (HbA1c) was detected by ion exchange high performance liquid chromatography. Serum MALAT1 expression level was detected by real-time fluorescence quantitative PCR. Pearson was used to analyze the correlation between MALAT1 and other clinical indexes of patients; the binary logistic regression was used to analyze the influencing factors of DR in T2DM patients; the receiver operating characteristic curve (ROC) was used to analyze the value of MALAT1 in DR predicting, and the area under curve (AUC), sensitivity and specificity were calculated. Results　The age, LDL-C, HbA1c, HOMA-IR, IL-6, TNF-α and MALAT1 of the proliferation group and the non-proliferation group were higher than those of the non-DR group (all P<0.05), and the above indexes of the proliferation group were higher than those of the non-proliferation group (all P<0.05). There was no significant difference in gender, body mass index, pathogenesis, proportions of hypertension, hyperlipidemia, smoking and drinking, AST, ALT, Scr, SUA, TC, TG, HDL-C and FBG among the three groups (all P>0.05). MALAT1 was positively associated with pathogenesis, LDL-C, HbA1c, HOMA-IR, IL-6 and TNF-α (all P<0.05), but not associated with AST, ALT, Scr, SUA, TC, TG, HDL-C and FBG (all P>0.05). Age, pathogenesis, LDL-C, HbA1c, HOMA-IR, IL-6, TNF-α and MALAT1 were independent influencing factors of DR in T2DM patients (all P<0.05). The AUC of MALAT1 for predicting DR in T2DM patients was 0.843, which was higher than that of LDL-C (0.464), HbA1c (0.606), HOMA-IR (0.601), IL-6 (0.663) and TNF-α (0.694). The sensitivity and specificity of MALAT1 in predicting DR in T2DM patients were 89.34% and 71.55%, respectively. Conclusion　The expression level of MALAT1 in serum increases when DR occurs in T2DM patients, and it is related to glucose and lipid metabolism, inflammatory markers and disease progression. MALAT1 may be a biological indicator for predicting DR in T2DM patients.

参考文献/References:

［1］　ANTONETTI D A,SILVA P S,STITT A W.Current understanding of the molecular and cellular pathology of diabetic retinopathy［J］.Nat Rev Endocrinol,2021,17(4):195-206.
［2］　LELEY S P,CIULLA T A,BHATWADEKAR A D.Diabetic retinopathy in the aging population:a perspective of pathogenesis and treatment［J］.Clin Interv Aging,2021,16:1367-1378.
［3］　HUANG Q,LI J.Research progress of lncRNAs in diabetic retinopathy［J］.Eur J Ophthalmol,2021,31(4):1606-1617.
［4］　许瑶,娄静,赵峰.LncRNAXIST/miR137/Notch1在糖尿病视网膜病变患者血清和玻璃体中的表达及机制［J］.实用医学杂志,2020,36(17):2409-2414.
XU Y,LOU J,ZHAO F.Expression and mechanism of LncRNAXIST/miR137/Notch1 in serum and vitreous of patients with diabetes retinopathy［J］.J Pract Med,2020,36(17):2409-2414.
［5］　GUTSCHNER T,HAMMERLE M,EISSMANN M,HSU J,KIM Y,HUNG G,et al.The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells［J］.Cancer Res,2013,73(3):1180-1189.
［6］　GORDON A D,BISWAS S,FENG B,CHAKRABARTI S.MALAT1:a regulator of inflammatory cytokines in diabetic complications［J］.Endocrinol Diabetes Metab,2018,1(2):e00010.
［7］　LIU P,JIA S B,SHI J M,LI W J,TANG L S,ZHU X H,et al.LncRNA-MALAT1 promotes neovascularization in diabetic retinopathy through regulating miR-125b/VE-cadherin axis［J］.Biosci Rep,2019,39(5):BSR20181469.
［8］　中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)［J］.中国实用内科杂志,2018,38(4):292-344.
Chinese Diabetes Society.Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition)［J］.Chin J Pract Intern Med,2018,38(4):292-344.
［9］　张天垚.血糖波动与糖尿病视网膜病变的相关性［J］.医学研究生学报,2020,33(11):1228-1232.
ZHANG T Y.The correlation between glucose variability and diabetic retinopathy［J］.J Med Postgrad,2020,33(11):1228-1232.
［10］　LU J,WU J,ZHAO Z,WANG J M,CHEN Z.Circulating LncRNA serve as Fingerprint for gestational diabetes mellitus associated with risk of macrosomia［J］.Cell Physiol Biochem,2018,48(3):1012-1018.
［11］　王中原,孙劲禹,谢田华,殷丽,姚勇.长链非编码RNA在糖尿病视网膜病变发病机制中的作用［J］.眼科新进展,2020,40(5):487-491,496.
WANG Z Y,SUN J Y,XIE T H,YIN L,YAO Y.Research progress on role of lncRNA in diabetic retinopathy［J］.Rec Adv Ophthalmol,2020,40(5):487-491,496.
［12］　BACCI L,BARBATI S A,COLUSSI C,AIELLO A,ISIDORI A M,GRASSI C,et al.Sildenafil normalizes MALAT1 level in diabetic cardiomyopathy［J］.Endocrine,2018,62(1):259-262.
［13］　ABDULLE L E,HAO J L,PANT O P,LIU X F,ZHOU D D,GAO Y,et al.MALAT1 as a diagnostic and therapeutic target in diabetes-related complications:a promising long-noncoding RNA［J］.Int J Med Sci,2019,16(4):548-555.
［14］　LIU J Y,YAO J,LI X M,WANG X Q,LI Y J,YAN B,et al.Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus［J］.Cell Death Dis,2014,5(10):e1506.
［15］　BISWAS S,THOMAS A A,CHEN S,AREF-ESHGHI E,FENG B,GONDER J,et al.MALAT1:an epigenetic regulator of inflammation in diabetic retinopathy［J］.Sci Rep,2018,8(1):6526.
［16］　WU G,LIU B,WU Q,TANG C,DU Z,FANG Y,et al.Correlations between different angiogenic and inflammatory factors in vitreous fluid of eyes with proliferative diabetic retinopathy［J］.Front Med (Lausanne),2021,8:727407.

相似文献/References:

[1]丁文君 韦琦 梁皓 陈金卯 李霞 谭少健.糖尿病兔后发性白内障发生过程中晶状体上皮细胞增殖的变化[J].眼科新进展,2012,32(1):000.
[2]陈放 徐珊 吕伟红 程宏 张洪泉.糖尿病大鼠视网膜的氧化应激损伤及葛根素对其的干预作用[J].眼科新进展,2012,32(1):000.
[3]李晓艳 张卯年.褪黑素对糖尿病大鼠早期视网膜神经细胞凋亡的影响[J].眼科新进展,2012,32(6):000.
[4]楚静 陈忠平.普拉洛芬及羟苯磺酸钙在糖尿病患者白内障手术中的应用[J].眼科新进展,2013,33(8):000.
[5]张曙光 何跃 项杰 马林昆 李燕 袁援生.JNK2在早期糖尿病小鼠视网膜中的表达及作用[J].眼科新进展,2012,32(4):000.
[6]李艳 潘斌 李筱荣 袁佳琴 张杰.糖尿病大鼠视网膜PEDF表达与神经退行性改变[J].眼科新进展,2012,32(8):000.
[7]崔颖 郭海科 韩云飞 孟倩丽 张良 尹东明.2型糖尿病住院患者糖尿病视网膜病变患病率及危险因素分析[J].眼科新进展,2012,32(8):000.
[8]张谊 宋光辉 杨架林 张钰 肖强 潘璐 赵伟红 刘昊.糖尿病患者短期内血糖变化对黄斑区视网膜厚度的影响[J].眼科新进展,2012,32(10):000.
[9]赵恳.白内障超声乳化人工晶状体植入术对糖尿病患者角膜内皮细胞形态与功能的影响[J].眼科新进展,2013,33(4):000.
[10]张立新 崔颖 孟倩丽 张敏 罗中伶 刘辉焜 朱国平 香淦媚 刘清洋 郭海科 郑洋 蔡晶晶. 广东省东莞市2型糖尿病患者盲与低视力患病率及原因分析[J].眼科新进展,2014,34(1):046.

备注/Memo

备注/Memo:
遂宁市中心医院科研基金资助项目（编号：2019y51）
更新日期/Last Update: 2022-12-05